US EditionEmergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a Potential 107.69% Upside
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a Potential 107.69% Upside
Emergent BioSolutions Inc. (NYSE: EBS) stands out in the healthcare sector as a key player in the specialty and generic drug manufacturing industry. With its focus on preparedness and response solutions for public health threats, the company offers an array of critical products ranging from the NARCAN Nasal Spray for opioid overdoses to vaccines for anthrax and smallpox, among others. Headquartered in Gaithersburg, Maryland, this life sciences c…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
